Consumer products group Reckitt Benckiser posted a trading update for its first quarter on Friday, reporting it was in line with expectations with continued strong performance in the health division led by Mucinex and Durex.
The FTSE 100 firm said that growth was offset by headwind in Scholl / Amopé, which also impacted Europe-North America performance.
Growth rates were set to improve through the year, and RB said it was on track for its full year net revenue target of 3% like-for-like.
This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.